AnalyST & Brugada Syndrome - Feasibility Study

Sponsor
Abbott Medical Devices (Industry)
Overall Status
Completed
CT.gov ID
NCT02052765
Collaborator
(none)
16
1
1
2.9
5.5

Study Details

Study Description

Brief Summary

Brugada syndrome is characterized by a ST shift on the surface ECG, and a specific morphology of the Twave. This ECG abnormality is called a type 1-ECG, and is variable in time. Patients presenting a Brugada syndrome are exposed to sudden cardiac death, although it's difficult to predict patients at high risk. It is suspected that the type 1-ECG burden might be correlated to the ventricular fibrillation risk of these patients, but there is no mean to record the ECG over a long period of time.

The objective of the study is to evaluate the correlation between ST elevation on the electrocardiogram (ECG) and ST shift on the intracardiac electrograms (EGM) recorded with the AnalyST ICD, to assess the ability of the device to detect the type 1-ECG. Patients enrolled in the study are patients already implanted with a defibrillator for their Brugada syndrome. During an Ajmalin test, which unmasks the type 1-ECG, both intracardiac EGM and surface ECG will be compared to assess the detection of the typical ST-shift by the ICD.

Condition or Disease Intervention/Treatment Phase
  • Device: ECG continuous recording (Analyze ST)
N/A

Detailed Description

To evaluate the correlation between ST elevation on the ECG and ST shift on the intracardiac EGM recorded with the AnalyST ICD, patients enrolled will have to be already diagnosed as presenting the Brugada Syndrome. They will undergo an ajmaline test, to unmask the type 1-ECG, characteristic from the Brugada syndrome.During the test, both surface ECG and intracardiac signal will be continuously recorded; then the signals will be compared in terms of amplitude of the ST shift, duration of the shift, and recovery period.

Study Design

Study Type:
Interventional
Actual Enrollment :
16 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
AnalyST & Brugada Syndrome - Feasibility Study
Study Start Date :
Feb 1, 2011
Actual Primary Completion Date :
May 1, 2011
Actual Study Completion Date :
May 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Experimental: ajmaline test

All patients underwent ajmaline test for ST shift recording

Device: ECG continuous recording (Analyze ST)
During the ajmaline test, continuous ECG recording was forced to record ST shift
Other Names:
  • Analyze ST
  • Outcome Measures

    Primary Outcome Measures

    1. ST shift correlation [Acute testing - 4h after the beginning of the ajmaline test.]

      Correlation between external ECG - ST elevation and device-recorded ST shift. The ajmaline is the reference method to unmask type 1-ECG in Brugada syndrome. During an ajmaline test, both surface ECG and intracardial EGM will be continuously recorded and compared to allow comparison of the signals in terms of amplitude and duration of the ST shift and recovery timing.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patients with Brugada syndrome and previous positive Ajmalin test

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hopital Laennec Nantes France 44000

    Sponsors and Collaborators

    • Abbott Medical Devices

    Investigators

    • Principal Investigator: Vincent Probst, M.D., Hopital Laennec

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Abbott Medical Devices
    ClinicalTrials.gov Identifier:
    NCT02052765
    Other Study ID Numbers:
    • CR-10-022-FR-HV
    First Posted:
    Feb 3, 2014
    Last Update Posted:
    Feb 4, 2019
    Last Verified:
    Feb 1, 2019
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 4, 2019